FleetPulse | $11,000,000 | (May 10, 2024)
ArkeaBio™ | $26,500,000 | (May 10, 2024)
Bluejay Therapeutics | $182,000,000 | (May 10, 2024)
QurAlis
United States
- Cambridge, MA
- 10/03/2023
- Series B
- $88,000,000
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.
- Industry Biotechnology
- Website https://quralis.com/
- LinkedIn https://www.linkedin.com/company/quralis1/
Related People
Kasper RoetFounder
United States -
Greater Boston
The maturation of patient derived stem technologies has made it possible to study clinical disease mechanisms in motor neurons derived from patients suffering from Amyotrophic Lateral Sclerosis (ALS). This is called "disease in a dish". We use this technology to find out what is wrong with patients and to identify new therapies and bring these back to the patient. It's a precision medicine approach with has been successful in combating cancer and we apply this now to conquer ALS!
CoverTree | $13,000,000 | (May 10, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Archive Intel | $1,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Triomics | $15,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Electricity Maps | $5,390,775 | (May 10, 2024)
Sift Healthcare | $20,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)
Chip City | $7,500,000 | (May 10, 2024)